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METHODS: It is an epidemiological, observational, cross-
sectional and descriptive study. There were included mild or
severe COPD patients (according to FEV1 value). There were
collected demographic, clinical and comorbidity data. The
patients were asked to ﬁll the MOS SF-12 questionnaire.
RESULTS: A total of 10,711 patients were collected [75.6%
were male, 53.4% had moderate COPD (FEV1: 40–59%),
18.9% were active smokers and 21.8% were obese (CMI >/=
30)], with a mean age of 67.1 + 9.6 years and a COPD time evo-
lution period of 10.4 + 7.3 years. The 14.6% of the patients
answered that their health was bad and 55.4% could not make
the diary life activities because of their disease. Country nor-
malized physical (PCS) and mental health (MCS) component
summary scores (SF-12) indicated signiﬁcant impairment in both
domains compared to the general Spanish population: PCS; 36.0
+ 9.9 vs. 50.1 + 9.5, and MCS; 48.3 + 10.9 vs. 50.0 + 9.6, respec-
tively. PCS deteriorated independently with both age and sever-
ity of COPD, (p < 0.0001 in all cases), but no differences were
seen by smoking habit after adjusting by age, sex and severity.
PCS also deteriorated with number of hospitalizations and exac-
erbations (p < 0.0001), and in obese subjects (p < 0.0001). As
expected, MCS deteriorated slightly with age (p < 0.01), but no
differences were seen according to severity of disease. After
adjusting, non smoker and ex-smokers showed better MCS than
active smokers (p < 0.05). MCS also deteriorated with number
of hospitalizations and exacerbations (p < 0.001). CONCLU-
SIONS: COPD decreases patients’ physical and mental compo-
nents of QoL, while increasing level of disability in Spain. The
impairment in QoL increases with age, severity and exacerba-
tions of COPD.
RESPIRATORY DISEASES/DISORDERS
RESPIRATORY DISEASES/DISORDERS—Health Policy
PRS8
IMPACT ON USE AND COST OF MEDICINES OF EXPANDED
DRUG COVERAGE VIA POSITIVE LIST IN THE PHILIPPINES
Valera M
Philippine Health Insurance Corporation, Manila, Philippines
We examined the effects of expanded drug coverage, known as
the positive list, on the use and cost of medicines in three selected
areas of the Philippines. OBJECTIVES: To determine the impact
of the expanded drug coverage (positive list) on the drug uti-
lization, appropriateness and drug costs of managing pneumo-
nia, hypertension and other upper respiratory tract infections.
METHODS: A time series design consisting of 12 monthly time
points immediately before and after a 3-month implementation
period of the Positive List was used. A total of 24 hospitals were
randomly selected from major urban centers in the 3 main
islands of the country: National Capital Region (n = 12), Davao
(n = 6) and Cebu/Dumaguete (n = 6). The main outcome vari-
ables were changes in levels and trends from baseline in monthly
mean numbers of prescriptions per patient, monthly percentages
of antibiotic prescriptions, monthly average percentages of pre-
scriptions which were listed in the national formulary and Posi-
tive List, monthly mean appropriateness scores and monthly
total drug costs. RESULTS: A total of 8206 patient records from
24 hospitals were reviewed. Among patients with pneumonia,
the implementation of the Positive List was not signiﬁcantly asso-
ciated with changes in monthly mean number of prescriptions,
percentage of positive list drugs, percentage of generic prescrip-
tions, and mean cost of drugs per patient. Trends in appropri-
ateness scores were observed to remain steady before and after
the implementation of the expanded drug coverage. CONCLU-
SIONS: The implementation of the expanded drug coverage in
October 2000 had no effect on prescription rates, generic pre-
scription, and choice of antibiotic prescriptions. On the other
hand, the monthly percent prescriptions of drugs belonging in
the positive list was decreasing slowly before the policy and
increasing somewhat after.
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OBJECTIVES: We took into consideration clinical effectiveness,
costs and macroeconomic consequences of supplementation with
two slow release kalium compounds (Kalipoz prolongatum vs
Kaldyum) from payer (public insurer and patient) perspective.
METHODS: Results of a systematic review of clinical trials
referring to hypokaliemia treatment were used to assess effects
of kalium supplementation with Kalipoz or Kaldyum. DDD
(Deﬁned Daily Dose) costs for supplementation were calculated
from payer perspective (based on retailed prices of the drugs);
simulation was done to compare economic consequences per
therapy for payer in case of Kaldyum replacement by Kalipoz;
total annual sales of the drugs in Poland were taken into account
to assess macroeconomic consequences of kalium supplementa-
tion. RESULTS: Clinical effects of the compared drugs are
similar, adequate level of kalium in blood could be obtained with
both of the drugs. DDD for potassium chloride compounds is 3
g; cost of daily supplementation for payer is 1.36pln (0.3€) in
case of Kalipoz and 2.24pln (0.48€) or 2.5pln (0.54€) for
Kaldyum tablets (for 100 caps and 50 caps package respectively).
Supplementation for a period of a week with high dose (3g) of
Kalipoz is cheaper from payer perspective than with Kaldyum
100 caps and Kaldyum 50 caps (difference is 6.18pln (1.34€)
and 7.98pln (1.73€) respectively). Taking into consideration
macroeconomic consequences of potassium supplementation
savings for payer when use Kalipoz in place of Kaldyum could
be as high as 5.6mpln (1.2€m) per year. CONCLUSIONS:
Kalipoz prolongatum in place of Kaldyum supplementation 
signiﬁcantly reduce treatment costs for payer in treatment of
patients with hypokaliemia.
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OBJECTIVES: The HIV and HCV epidemics of the 1980’s and
1990’s highlighted the vulnerability of hemophilia patients to the
transmission of unknown blood-borne infections. Consequently,
the pharmaceutical industry has been charged with developing
recombinant concentrates with the least amount of human 
or animal proteins in order to reduce the chance of infection 
by emerging blood-borne infectious agents (e.g., viruses,
prions/nvCJD). In response, Antihemophilic Factor (recombi-
